Elektrofi Stock
HealthTechLooking to sell Elektrofi stock or options?
Elektrofi has developed a drug delivery platform aimed at enhancing subcutaneous administration. Their formulation system efficiently processes a wide range of therapeutic molecules, and their technology is capable of handling large, complex, and delicate proteins, such as monoclonal antibodies, as well as bispecific and fusion proteins. This enables drug manufacturers to create groundbreaking therapies with ease, empowering patients to have control over how they receive and benefit from transformative medicines.
Novo Holdings, Charlotte Angel Fund, Leerink Partners, Eli Lilly and Company, Catalio Capital Management, Flobas Ventures, Paradigm BioCapital, Samsara BioCapital, Woodline Partners, Royalty Pharma, RA Capital Management, BVF Partners, Marshall Wace, Checkpoint Capital, General Catalyst, TPG, SR One Capital Management, Braidwell, Janus Henderson Investors, National Science Foundation, Deep Track Capital, Logos Capital, Kearny Venture Partners.